000			03116nam a22004457a 4500
008			240807s20232023 xxu||||| |||| 00| 0 eng d
022			_a2352-3727
024			_aBLC220027 [pii]
024			_aPMC11181828 [pmc]
040			_aOvid MEDLINE(R)
099			_a38994485
245			_aEconomic Outcomes of Hexaminolevulinate Blue-Light Cystoscopy in Non-Muscle Invasive Bladder Cancer: A 5-Year, Medicare-Based Model.
251			_aBladder Cancer. 9(1):87-96, 2023.
252			_aBladder Cancer. 9(1):87-96, 2023.
253			_aBladder cancer (Amsterdam, Netherlands)
260			_c2023
260			_fFY2023
260			_p2023
265			_sepublish
265			_tPubMed-not-MEDLINE
266			_d2024-08-07
266			_z2024/07/12 04:51
520			_aBACKGROUND: Bladder cancer is the most expensive cancer to treat on a per-patient basis. Blue light cystoscopy with hexaminolevulinate (BLC) has demonstrated improved diagnostic accuracy compared with white light cystoscopy (WLC) in non-muscle invasive bladder cancer (NMIBC). With higher upfront costs, questions remain about long-term BLC cost outcomes.
520			_aCONCLUSIONS: Despite a higher initial annual cost, a slight cumulative economic advantage of BLC is realized after surveillance year 3. Additionally, a greater proportion of patients who received BLC achieved cost savings at the end of year 5. As novel technology emerges, economic models can help health care systems predict associated costs and quality improvements. Copyright © 2023 - The authors. Published by IOS Press.
520			_aMETHODS: A representative 5-year NMIBC management model was constructed and Medicare reimbursement values were overlaid. The primary outcome was mean year-over-year cumulative cost discounted to present value at a 3% annual percentage rate. The secondary outcome was the rate of clinical events.
520			_aOBJECTIVE: This study seeks to investigate the 5-year cost comparison of BLC and WLC from the Medicare payer perspective.
520			_aRESULTS: Patients in the BLC cohort experienced fewer recurrences. On a cumulative present value cost basis, BLC was more expensive per patient in years 1, 2, and 3 than WLC, however, in years 4 and 5, BLC was economically favorable. Year 5 BLC mean cumulative cost savings was _1,172 per patient. Overall, 31.6% of all patients in the BLC group generated cumulative cost savings compared to WLC at year 1 compared with 50.9% at the end of year 5.
546			_aEnglish
650			_zAutomated
651			_aMedStar Washington Hospital Center
656			_aMedStar Georgetown University Hospital/MedStar Washington Hospital Center
656			_aUrology
656			_aUrology Residency - Categorical
657			_aJournal Article
700			_aMason, James _bMGUH _cUrology Residency - Categorical _dMD
700			_aStamatakis, Lambros _bMWHC
790			_aCreswell ML, Sholklapper TN, Markel MJ, Mason JB, Pianka MA, Dall CP, Ulu C, Stamatakis L
856			_uhttps://dx.doi.org/10.3233/BLC-220027 _zhttps://dx.doi.org/10.3233/BLC-220027
942			_cART _dArticle
999			_c14455 _d14455